Pharmacodynamics of antibiotics in the respiratory tree

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 1, 2004, Pages 15-23

  Bergogne Bérézin, Eugénie ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Antibiotic; Pharmacodynamics; Pharmacokinetics; Pharmacology; Respiratory infections; Respiratory tree; Tissue concentrations

Indexed keywords

14 HYDROXYCLARITHROMYCIN; AMIKACIN; AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CARBENICILLIN; CEFALEXIN; CEFALOTIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFPIROME; CEFPODOXIME PROXETIL; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; DIRITHROMYCIN; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LATAMOXEF; MEZLOCILLIN; OFLOXACIN; PIPERACILLIN; ROXITHROMYCIN; SPIRAMYCIN; TOBRAMYCIN; UNINDEXED DRUG;

AREA UNDER THE CURVE; COST BENEFIT ANALYSIS; CYSTIC FIBROSIS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; DRUG UPTAKE; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; LUNG FLUID; MEDICAL ETHICS; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRESCRIPTION; PROCESS MODEL; RESPIRATORY TRACT INFECTION; REVIEW; SERUM;

EID: 9144250215     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.1.15     Document Type: Review

References (53)

1. CARBON C: Significance of tissue levels for prediction of antibiotic efficacy and determination of dosage. Eur. J. clin. Microbiol. Infect. Dis. (1990) 9:510-516.
2. BERGOGNE-BÉRÉZIN E.: Predicting the efficacy of antimicrobial agents in respiratory infections: is tissue concentration a valid measure? J. Antimicrob. Chemother. (1995) 35:363-371.
3. NIX DE: Intrapulmonary concentrations of antimicrobial agents. Infect. Dis. Clin. North Am. (1998) 12:631-646.
4. HONEYBOURNE D, BALDWIN DR: The site concentrations of antimicrobial agents in the lung. J. Antimicrob. Chemother. (1992) 30:249-260.
5. HONEYBOURNE D: Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. Curr. Opin. Pulm. Med. (1997) 3:170-174.
6. BERGOGNE-BEREZIN E: New concepts in the pulmonary disposition of antibiotics. Pulm. Pharmacol. (1995) 8:65-81.
7. BARZA M: Tissue-directed antibiotic therapy: antibiotic dynamics in cells and tissue. Challenges to antibiotic activity in tissue. Clin. Infect. Dis. (1994) 19:910-915.
8. NIX DE, GOODWIN SD, PELOQUIN CA, ROTELLA DL, SCHENTAG JJ: Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob. Agents. Chemother. (1991) 35:1947-1952.
9. EMMERSON AM: The clinical significance of tissue concentrations. Res. Clin. Forums (1990) 12:117-121.
10. DRUSANO GL: Role of pharmacokinetics in outcome of infectious. Antimicrob. Agents. Chemother. (1988) 32:289-297.
11. DE LOUVOIS J: Factors influencing the assay of antimicrobial drugs in clinical samples. J. Antimicrob. Chemother. (1982) 9:253-265.
12. JEHL F: High performance liquid chromatography of antibiotics. J. Chromatogr. (1990) 531:509-548.
13. JELLIFFE R, SCHUMITZKY A, VAN GUILDER M et al.: Individualizing drug dosage regimen: role of population pharmacokinetic models, bayesian fitting, and adaptive control. Therap. Drug Monit. (1993) 15:390-393.
14. BOUVIER D'YVOIRE MJY, MAIRE PAH: Dosage regimens of antibacterials: implications of phamacokinetics/pharmacodynamic model. Therap. Drug Monit. (1996) 11:229-239.
15. SCHENTAG JJ. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with Gram-negative pneumonia. Scand. J. Infect. Dis. (1991) 74(Suppl.):218-234.
16. CRAIG WA: Pharmacokinetic/ pharmacodynamic parameters: rationale for antibacterial dosing in mice and men. Clin. Infect. Dis. (1998) 26:1-12.
17. PRAM LH, BRUN-BUISSON C, LEGRAND P et al.: Diagnosis of nosocomial pneumonia in mechanically ventilated patients. Comparison of a plugged telescoping catheter with the protected specimen brush. Am. Rev. Respir. Dis. (1991) 143:1055-1061.
18. BALDWIN DR. WISE R, ANDREWS JM et al: Microlavage: a technique for determining the volume of epithelial lining fluid. Thorax (1991) 46:658-662.
19. MEYERS BM, WILKINSON P: Clinical pharmacokinetics of antibacterial drugs in the elderly. Implications for selection and dosage. Clin. Pharmacokinet. (1989) 17:385-395.
20. SINGLAS E: Bases pharmacocinétiques de l'adaptation posologique chez l'insuffisant rénal chronique. In: 'Séminaire d'uronéphrologie. Pitié-Salpêtrièrè. Chatelain C, Jacobs C (Eds ), Masson, Paris, France (1993).102-111.
21. KOSCOVE EM: Sepsis and septic shock. In: Infectious diseases in emergency medicine (2nd edn). Brillman JC, Quenzer RW (Eds), Lippincott, Raven Publishers, USA (1997):129-152.
22. CHARTRAND SA. MARKS MI: Pulmonary infections in cystic fibrosis: pathogenesis and therapy. In: Respiratory infections: diagnosis and management, Pennington JE (Ed.), Raven Press, New York, USA (1988):267-297.
23. MENDELMAN PM, SMITH AL, LEVY J, WEBER A. RAMSEY B, DAVIS RL: Aminoglycoside penetration, inactivation and efficacy in cystic fibrosis sputum. Am Rev. Respir. Dis (1985) 132:761-765.
24. ROUSSEY M, HUSSON MO, HUET F: Current concepts in fibrosis: pathogenesis, microbiology, new therapeutic approaches. Antibiotiques (2002) 4:203-224.
25. REBUCK AS,BRAUDE AC: Assessment of drug disposition in the lung. Drugs (1984) 28:544-553.
26. VALCKE Y, PAUWELS R, VAN DER STRETEN M. Pharmacokinetics of antibiotics in the lungs. Eur. Respir. J. (1990) 3:715-722.
27. RAOULT D, BROUQUI P: Intracellular location of microorganisms. In: Antimicrobial agents and intracellular Pathogens. Raoult D (Ed.), CRC Press, London, UK (1993):39-61.
28. VALLÉE E, AZOULAY-DUPUIS E. POCIDALO JJ, BERGOGNE-BÉRÉZIN E: Activity and local delivery of azithromycin in a mouse model of Haemophilus influenza lung injection. Antimcrob. Agents Chemother. (1992) 36:1412-1417.
29. VALLÉE E, AZOULAY-DUPUIS E, POCIDALO JJ, BERGOGNE-BÉRÉZIN E: Pharmacokinetics of four flouroquinolones in a mouse model of infected lung, J. Antimicrob, Chemother. (1991) 28(Suppl. C):39-44.
30. ZAK O, O'REILLY T. Animal models in the evaluation of antimicrobial agents. Antimicrob. Agents Chemother. (1991) 35:1527-1531.
31. FOULDS G, SHEPARD RM, JOHNSON RB: The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. (1990) 25(Suppl. A):73-82.
32. MARLIN GE, BURGESS KR, BURGOYNE J, FUNNELL GR, GUINNESS MDG: Penetration of piperacillin into bronchial mucosa and sputum. Thorax (1981) 36:774-780.
33. BRUN Y, FOREY F, GAMONDES JP: levels of erythromycin in pulmonary tissue and bronchial mucus compared to those of amoxycillin. J. Antimicrob. Chemother. (1981) 8:459-466.
34. FRASCHINI F, SCAGLIONE F, PINTUCCI G, MACCARINELLI G, DUGNANI S, DEMARTINI G: The diffusion of clarithromycin and roxithromycin into nasal mucosa tonsil and lung in humans. J. Antimicrob. Chemother. (1991) 27(Suppl. A):61-65.
35. BERGOGNE-BÉRÉZIN E: Tissue distribution of dirithromycin: comparison with erythomycin. J. Antimicrob. Chemother. (1993) 31(Suppl. C):77-87.
36. BALDWIN DR, HONEYBOURNE, D, WISE R: Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob. Agents Chemother. (1992) 36:1171-1175.
37. PANTEIX G, HARF R, DESNOTTES JF: Accumulation of pefloxacin in the lower respiratory tract demonstrated by bronchoalveolar lavage. J. Antimicrob. Chemotber. (1994) 33:979-985.
38. BRYSKIER A. Therapeutic alternatives in respiratory tract infections: contribution of levofloxacin. Antibiotiques (2000) 2:35-51.
39. LABRO MT: Interaction between antimicrobial drugs and phagocytes: an overview. Int. J. Antimicrob. Agents (1993) 3:73-87.
40. ROHWEDDER R. Tissue penetration of ciprofloxacin with special reference to the lung. In. Ciprofloxacin in pulmonology. Fas RJ (Ed.), W. Zuckschwerdt Verlag, München, Germany (1990):67-77.
41. CRAIG WA: Interrelationships between pharmacokinetics; and pharmacodynamics in determining dosage regimens for broad-spectrum-cephalosporins. Diagn. Microbiol. Infect. Dis. (1995) 22:89-96.
42. SCAGLIONE F., MOUTON JW, MATTINA R: Pharmacodynamics of levofloxacin in a murine pneumonia model: importance of peak to MIC ratio versus AUC. In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents in Chemotherapy. San Francisco, USA, September 26-29 (1999) (Abstract 20).
43. ROOSENDAAL R, BAKKER-WOUDENBER IA. Impact of the antibiotic dosage schedule on efficacy in experimental lung infections. Scand. J. Infect. Dis. (1999) 74(Suppl.):155-162.
44. FIRSOV A. ZINNER S, LUBENHKO I et al.: Prediction of the equivalent fluoroquinolone (FQ) AUC/MIC breakpoints (BPs) based on pharmacodynamic studies with in vitro dynamic models: in vitro - in vivo correlations. In: Program and abstract of the 39th Interscience Conference on Antimicrobial Agents in Chemotherapy, San Francisco, USA, September 26-29 (1999) (Abstract 24).
45. RODRIGUEZ-CERRATO V, MICHELOW IC, GHAFFAR F et al.: Pharmacodynamics and bactericidal activity of Moxifloxacin in experimental E. coli meningitis. In: Program and Abstracts ofthe 39th, Interscience Conference on Antimicrobial Agents in Chemotherapy., San Francisco, USA. September 26-29 (1999) (Abstract 29).
46. VOSTROV S, LUBENKO I, KONONENKI O et al.: Comparative pharmacodynamics of gemifloxacin and ciprofloxacin with Staphylococcus aureus Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model. In: Progam and Abstracts of the 39th Interscience Conference on Antimicrobial Agents in Chemotherapy; San Francisco, USA. Septemeber 26-29 (1999) (Abstract 26).
47. LEGGETT JE, FANTIN B, EBERT S et al.: Comparative antibiotic dose-effects relations at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. (1989) 159:281-292.
48. ROOSENDAL R, BAKKER-WOUNDENBERG IAJM, VAN DEN BERG JC et al.: Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental K. pneumoniae pneumonia in rats. J. Infect. Dis. (1985) 152:281-292.
49. HOULIHAN HH, MERCIER RC, MACKINNON PS et al.: Vontinuous infusion versus intermitent administration of ceftazidime in critically ill patients with Gram-negative infection. 37th Interscience Conference on Antimicrobial Agents in Chemothery. Toronto, Canada (1997) (Abstract A-42).
50. VINKS A, BRIMICOMBE RW, HEIJERMAN HGM: Continuous infusion of cefatzidime in adults cystic fibrosis patients during continuous infusion and ambulatory treatment at home: clinical outcome, microbiology and pharmacokinetics. J. Antimicrob. Chemother. (1997) 40:125-133.
51. BOSELLI E, BREIHL D, DUFLO F et al.: Steady state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomila pneumonia. Crit. Care Med. (2003) 31:2102-2106.
52. POWEL SH, THOMPSON WL, LUTHE MA et al.: Once daily versus continuous aminoglycoside dosing; efficacy and toxicity in animal and clinical studies of gentamycin, tobramycin and netilmicin. J. Infect. Dis, (1983) 147:918-932.
53. ELLNER PD, NEU HC: The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. J. Am. Med. Assoc. (1981) 246:1575-1578.